跳至主要内容
临床试验/NCT05097573
NCT05097573已完成不适用

Clinical Evaluation of the Efficacy of Fractional Radiofrequency for the Treatment and Reduction of Stretch Marks

Venus Concept1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2019年5月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Venus Concept
入组人数
17
试验地点
1
主要终点
Percent Change in Volume of Striae Via Antera 3D Imaging System Analysis From Baseline to 16 Weeks Post-final Treatment

研究概览

简要总结

This is a prospective, single centre, evaluator-blind study of the performance of fractional radiofrequency (RF) for the treatment and revision of stretch marks. The study will evaluate the progress of 15 subjects requesting treatment of stretch marks. The study will involve four treatments on both sides of the face with 4 week intervals between each treatment. Subjects will be followed at 12 and 16 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy, male or female subjects, 18-60 years of age who are seeking treatment for their stretch marks
  • Fitzpatrick skin type I-IV
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.

排除标准

  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  • Subjects with any implantable metal device in the treatment area
  • Permanent implant in the treated area, such as metal plates and screws (excluding dental implants), or an injected chemical substance.
  • Current or history of any kind of cancer, or dysplastic nevi in the treated area.
  • Severe concurrent conditions, such as cardiac disorders.
  • Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
  • History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.
  • Poorly controlled endocrine disorders, such as diabetes.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants.
  • Use of isotretinoin (Accutane®) or other systemic retinoids limited up to 10mg/day or as per investigators discretion.
  • Treating over tattoo or permanent makeup.
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

结局指标

主要结局

Percent Change in Volume of Striae Via Antera 3D Imaging System Analysis From Baseline to 16 Weeks Post-final Treatment

时间窗: 16 Weeks Post-Final Treatment (Week 28)

Change from baseline to the follow-up visit 16 weeks post-final treatment as a percentage of baseline volume.

Overall Stretch Mark Improvement From Baseline to 16 Weeks Post-Final Treatment Assessed by the Global Aesthetic Improvement Scale (GAIS)

时间窗: 16 Weeks Post-Final Treatment (Week 28)

Evaluate the efficacy of overall stretch mark improvement assessed live by the Investigator and a subject assessment of stretch mark including the Global Aesthetic Improvement Scale (GAIS).The Global Aesthetic Improvement Scale is a seven-grade subjective test. The PI evaluated before and after photographs and graded them for change. Possible responses were (3) Very Much Improved, (2) Much Improved, (1) Improved, (0) No Change, (-1) Worse, (-2) Much Worse, and (-3) Very Much Worse. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range -3 to 3).

次要结局

  • Subject Satisfaction(16 Weeks Post-Final Treatment (Week 28))
  • Subject Scale - 5 Point Scale for Treatment Tolerability(Treatment 1 (Week 1), Treatment 2 (Week 4), Treatment 3 (Week 8), Treatment 4 (Week 12))
  • Subject Scale - Visual Analog Scale for Pain(Treatment 1 (Week 1), Treatment 2 (Week 4), Treatment 3 (Week 8), Treatment 4 (Week 12))

研究者

发起方
Venus Concept
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验